News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article reports on a SCHEDULE 13D filing related to Colliers International Group. The filing is categorized under "Others," indicating the nature of the disclosure.
This article provides the coupon profile for the Collegium Pharmaceutical, Inc. bond, COLL5756983, detailing its interest rate and payment schedule. The bond has a current coupon rate of 2.88%, with the next payment planned for August 17, 2026. It offers an overview of the …
Collegium Pharmaceutical (COLL) has delivered a strong 59.6% return over the past three years, but its current valuation appears broadly inline with the market. The stock trades at a P/E of 15.6x, similar to the pharmaceutical industry average, suggesting it's neither significantly undervalued nor …
This article announces the filing of Form 144 for Collegium Pharmaceutical, dated July 17. Form 144 signals an insider's intent to sell restricted stock in the open market, an action of interest to investors tracking company-specific financial movements. The publication is from Investing.com and …
CollPlant Biotechnologies has filed to register for resale up to 31,047,068 ordinary shares by existing investors. These shares include PIPE shares and those issuable upon the exercise of various warrants from a June-July 2026 private placement. While CollPlant will not receive proceeds from the …
This article provides an algorithmic analysis of Collegium Pharmaceutical Inc. (NASDAQ: COLL), highlighting a near-term strong sentiment despite a neutral mid and long-term outlook. It details specific trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis …
Colliers International Group (CIGI) recently saw a slight decrease in its analyst consensus target to CA$207.63 due to updated fair value estimates. The company's Q2 2026 National Market Snapshot reported national office vacancy at 13.4% and industrial vacancy at 3.3%. Additionally, Colliers authorized a …
John A. Fallon, an insider at Collegium Pharmaceutical Inc. (COLL), has filed to sell 13,920 shares of common stock with an aggregate market value of $497,429.27, expected around July 17, 2026. This planned sale is related to a stock option exercise and follows a …
CollPlant Biotechnologies Ltd (CLGN) has announced an SEC filing, specifically a Notice of Effectiveness for Form F-3, dated July 16, 2026, at 4:00 P.M. The filing, with CIK 0001631487 and file number 333-297347, was accepted by SEC EDGAR on July 17, 2026. This indicates …
This article provides a list of Exchange Traded Funds (ETFs) that invest in Collegium Pharmaceutical, Inc. stocks, ordered by market value. It includes details such as issuer, management style, expense ratio, assets under management (AUM), and 3-year NAV total return for each ETF. The …
Colliers International Group Inc. (NASDAQ:CIGI) has received an average analyst rating of "Moderate Buy" from 12 analysts, with a 12-month average price target of approximately $159.11. Recent analyst actions were mixed, including price target cuts from Scotia and BMO Capital Markets, an upgrade from …
Sharemaestro market context Price below Trend Line 52 weeks -36.9% · Next-week setup positive 61.7%Colliers International (CIGI.O) announced a quarterly dividend of CAD 0.15 per share. The dividend is payable on July 31, 2026, to shareholders of record as of July 21, 2026.
This article provides key metrics for the COLL5756983 bond issued by Collegium Pharmaceutical, Inc. The bond has a 2.875% coupon rate, an issue date of February 16, 2024, and matures on February 15, 2029. It highlights the company as a biopharmaceutical firm focused on …
This article reports on a Form 144 SEC filing by COLLEGIUM PHARMACEUTICAL, INC. (COLL). The filing, dated July 15, 2026, details a proposed sale of 8,095 shares of common stock with an aggregate market value of $294,010.40 acquired through a stock option exercise, to …
Search by ticker symbol or company name and select a result to open its chart.